WO1999060988A3 - Combination therapy for treatment of fiv infection - Google Patents

Combination therapy for treatment of fiv infection Download PDF

Info

Publication number
WO1999060988A3
WO1999060988A3 PCT/US1999/011940 US9911940W WO9960988A3 WO 1999060988 A3 WO1999060988 A3 WO 1999060988A3 US 9911940 W US9911940 W US 9911940W WO 9960988 A3 WO9960988 A3 WO 9960988A3
Authority
WO
WIPO (PCT)
Prior art keywords
fiv infection
treatment
combination therapy
azt
methods
Prior art date
Application number
PCT/US1999/011940
Other languages
French (fr)
Other versions
WO1999060988A2 (en
WO1999060988A9 (en
Inventor
Ben M Dunn
Janet K Yamamoto
Maki Arai
Original Assignee
Univ Florida
Ben M Dunn
Janet K Yamamoto
Maki Arai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Ben M Dunn, Janet K Yamamoto, Maki Arai filed Critical Univ Florida
Priority to CA002374198A priority Critical patent/CA2374198A1/en
Priority to US09/763,037 priority patent/US6875773B1/en
Priority to AU42197/99A priority patent/AU4219799A/en
Priority to EP99926027A priority patent/EP1146882A2/en
Publication of WO1999060988A2 publication Critical patent/WO1999060988A2/en
Publication of WO1999060988A9 publication Critical patent/WO1999060988A9/en
Publication of WO1999060988A3 publication Critical patent/WO1999060988A3/en
Priority to US11/029,078 priority patent/US20050159389A1/en
Priority to US12/327,320 priority patent/US20090197827A1/en
Priority to US13/232,579 priority patent/US20120070489A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC and a retroviral protease inhibitor.
PCT/US1999/011940 1998-05-29 1999-05-28 Combination therapy for treatment of fiv infection WO1999060988A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002374198A CA2374198A1 (en) 1998-05-29 1999-05-28 Combination therapy for treatment of fiv infection
US09/763,037 US6875773B1 (en) 1998-05-29 1999-05-28 Combination therapy for treatment of FIV infection
AU42197/99A AU4219799A (en) 1998-05-29 1999-05-28 Combination therapy for treatment of fiv infection
EP99926027A EP1146882A2 (en) 1998-05-29 1999-05-28 Combination of zidovudine (azt) with nucleoside analogs for treatment of feline immunodeficiency virus
US11/029,078 US20050159389A1 (en) 1998-05-29 2005-01-04 Combination therapy for treatment of FIV infection
US12/327,320 US20090197827A1 (en) 1998-05-29 2008-12-03 Combination Therapy for Treatment of FIV Infection
US13/232,579 US20120070489A1 (en) 1998-05-29 2011-09-14 Combination therapy for treatment of fiv infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8728198P 1998-05-29 1998-05-29
US60/087,281 1998-05-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/763,037 A-371-Of-International US6875773B1 (en) 1998-05-29 1999-05-28 Combination therapy for treatment of FIV infection
US11/029,078 Continuation US20050159389A1 (en) 1998-05-29 2005-01-04 Combination therapy for treatment of FIV infection

Publications (3)

Publication Number Publication Date
WO1999060988A2 WO1999060988A2 (en) 1999-12-02
WO1999060988A9 WO1999060988A9 (en) 2000-02-24
WO1999060988A3 true WO1999060988A3 (en) 2000-12-07

Family

ID=22204237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011940 WO1999060988A2 (en) 1998-05-29 1999-05-28 Combination therapy for treatment of fiv infection

Country Status (4)

Country Link
EP (1) EP1146882A2 (en)
AU (1) AU4219799A (en)
CA (1) CA2374198A1 (en)
WO (1) WO1999060988A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067984A2 (en) 2001-02-22 2002-09-06 University Of Florida Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection
EP2731574B1 (en) * 2011-07-13 2017-03-15 White Cell RX Holdings Pty Ltd Medication management system

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022778A1 (en) * 1995-01-27 1996-08-01 Emory University Derivatives of succinamide and their use as metalloproteinase inhibitor
WO1996023509A1 (en) * 1995-02-01 1996-08-08 Merck & Co., Inc. Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc, optionally together with azt, ddi or ddc
WO1996030025A1 (en) * 1995-03-30 1996-10-03 The Wellcome Foundation Limited Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc
WO1997003055A1 (en) * 1995-07-13 1997-01-30 Sloan-Kettering Institute For Cancer Research Compounds, compositions, and methods for inhibiting replication of retroviruses and for inhibiting tumor promoter initiated transcription
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DE19703131A1 (en) * 1997-01-29 1998-07-30 Bayer Ag Use of quinoxaline in a combination of three with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of AIDS and / or HIV infections
WO1999055372A1 (en) * 1998-04-29 1999-11-04 Glaxo Group Limited Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
WO1999066936A1 (en) * 1998-06-24 1999-12-29 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022778A1 (en) * 1995-01-27 1996-08-01 Emory University Derivatives of succinamide and their use as metalloproteinase inhibitor
WO1996023509A1 (en) * 1995-02-01 1996-08-08 Merck & Co., Inc. Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc, optionally together with azt, ddi or ddc
WO1996030025A1 (en) * 1995-03-30 1996-10-03 The Wellcome Foundation Limited Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc
WO1997003055A1 (en) * 1995-07-13 1997-01-30 Sloan-Kettering Institute For Cancer Research Compounds, compositions, and methods for inhibiting replication of retroviruses and for inhibiting tumor promoter initiated transcription
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DE19703131A1 (en) * 1997-01-29 1998-07-30 Bayer Ag Use of quinoxaline in a combination of three with protease inhibitors and reverse transcriptase inhibitors as medicaments for the treatment of AIDS and / or HIV infections
WO1999055372A1 (en) * 1998-04-29 1999-11-04 Glaxo Group Limited Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
WO1999066936A1 (en) * 1998-06-24 1999-12-29 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SMITH R A ET AL: "A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.", JOURNAL OF VIROLOGY, (1998 MAR) 72 (3) 2335-40., XP000891901 *
SMITH R.A. ET AL: "A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.", JOURNAL OF VIROLOGY, (1997) 71/3 (2357-2362)., XP000891900 *
SMYTH N.R. ET AL: "Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents.", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, (1994) 34/4 (589-594)., XP000904799 *

Also Published As

Publication number Publication date
CA2374198A1 (en) 1999-12-02
AU4219799A (en) 1999-12-13
WO1999060988A2 (en) 1999-12-02
WO1999060988A9 (en) 2000-02-24
EP1146882A2 (en) 2001-10-24

Similar Documents

Publication Publication Date Title
EP0781136A4 (en) Compounds and methods for the treatment of cancer
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
ES2161785T3 (en) EMPLASTO FOR THE TREATMENT OF UNGULAR MICOSIS.
BR0317747A (en) Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment
EP0831832A4 (en) Methods of combatting infectious diseases using dicationic bis-benzimidazoles
ATE218854T1 (en) TREATMENT OF CARDIAC ARTHRY DISORDERS BY INHIBITING A MULTIFUNCTIONAL CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE
PT1052905E (en) ANTI-GERMINATIVE PROCESS OF TUBERCULOS AND BOLBOS USING EUGENOL AND / OR ISOEUGENOL
DE69116380T2 (en) PHARMACEUTICAL PREPARATION FOR TREATING EXTENDED COAGLING TIME
DE69623390D1 (en) Active implantable medical device, in particular pacemaker or defibrillator
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
PT855916E (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ACTIVINE OR INHIBIT STIMULATOR
WO1999060988A3 (en) Combination therapy for treatment of fiv infection
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
EP0967276A3 (en) Anti-tumor agent comprising salmosin
ATE344664T1 (en) IMPROVED METHOD FOR ERADICATION OF HELICOBACTER PYLORI
FR2786100B1 (en) NEW THERAPEUTIC APPLICATION OF NICERGOLIN
YU60199A (en) New bpc peptide salts with organo-protective activity,the process for their preparation and their use in therapy
ES2190581T3 (en) 2-OPTICALLY ACTIVE AMINOTETRALINE, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT, ACTIVE IN THE PREVENTION AND TREATMENT OF SEPTIC SHOCK.
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
WO1998042325A3 (en) INHIBITION OF THE CLEAVAGE OF PRECURSOR IL-1$g(b)
BR9708037A (en) Method for the treatment of substance abuse
DK664188D0 (en) BUTYL HYDROXYANISOLS FOR TREATING RETROVIRAL DISEASES
IT240104Y1 (en) DEVICE FOR THE TREATMENT OF THE HUMAN BODY.
DE69737088D1 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF FIV INFECTIONS
ATE306278T1 (en) TREATING BONE DISEASES WITH ADRENOMEDULLIN

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 12 AND 13, DESCRIPTION, REPLACED BY NEW PAGES 12 AND 13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999926027

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09763037

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999926027

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2374198

Country of ref document: CA

Ref country code: CA

Ref document number: 2374198

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1999926027

Country of ref document: EP